Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
protease inhibitor |
| gptkbp:CASNumber |
1227911-45-6
|
| gptkbp:criteria |
highly selective for PDK1
|
| gptkbp:developedBy |
GlaxoSmithKline
|
| gptkbp:hasMolecularFormula |
C18H27N7O2
|
| gptkbp:hasSMILES |
CC1=CC(=NN1CC2=NC(=NC(=N2)NCC(C)(C)O)N3CCOCC3)C
|
| https://www.w3.org/2000/01/rdf-schema#label |
PDK1 inhibitor GSK2334470
|
| gptkbp:inhibitedBy |
gptkb:3-phosphoinositide-dependent_protein_kinase-1
|
| gptkbp:IUPACName |
4-[(3,5-dimethyl-1H-pyrazol-4-yl)methyl]-N-(2-hydroxy-1,1-dimethylethyl)-6-(4-morpholinyl)-1,3,5-triazin-2-amine
|
| gptkbp:molecularWeight |
373.45 g/mol
|
| gptkbp:PubChem_CID |
25154816
CHEMBL1800372 |
| gptkbp:synonym |
gptkb:GSK2334470
gptkb:GSK-2334470 |
| gptkbp:target |
gptkb:PDK1
|
| gptkbp:usedInResearchOn |
gptkb:cancer
cell signaling |
| gptkbp:bfsParent |
gptkb:GSK2334470
|
| gptkbp:bfsLayer |
7
|